Eversept Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-470,506
Closed -$21.6M 79
2022
Q1
$21.6M Sell
470,506
-193,978
-29% -$9.25M 1.66% 22
2021
Q4
$40.7M Sell
664,484
-25,017
-4% -$1.73M 2.6% 11
2021
Q3
$51.5M Sell
689,501
-83,979
-11% -$7.05M 3.56% 10
2021
Q2
$71.5M Sell
773,480
-33,452
-4% -$2.84M 4.77% 5
2021
Q1
$71.6M Buy
+806,932
New +$80M 5.38% 3

Other funds holding ARKG

Eversept Partners's ARKG Position: Q2 2022 in Review

Eversept Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 470,506 shares — an estimated $21.6M sold.

Eversept Partners first reported a position in ARKG in Q1 2021 and held it in 5 quarters. The position peaked at $71.6M in Q1 2021. 334 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • Eversept Partners reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • Eversept Partners sold 470,506 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $21.6M.
  • Eversept Partners first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 5 quarters.
  • Eversept Partners's ARK Genomic Revolution ETF position peaked at $71.6M in Q1 2021.
  • 334 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.